Topic and direction labels are AI-assisted, and each one quotes the bill text it is based on.
How labels work
Federal · 119th Congress
HR7902Safeguarding Women from Chemical Abortion Act
Direction
Abortionmedication abortionAI label
↓Restricts abortion accessmodel confidence 95%
Deems FDA approval of mifepristone for terminating intrauterine pregnancy withdrawn and treats its distribution as a violation, so less medication-abortion access.
Approval of an application submitted under subsection (b) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for the drug mifepristone (marketed as Mifeprex, and also known as RU-486) with an indication for the termination of intrauterine pregnancy, and of any application submitted under subsection (j) of such section for a drug with the same indication and for which mifepristone is the reference drug, is deemed to have been withdrawn under subsection (e) of such section.
✓ Quote verified word for word in the bill text
Abortionprovider clinic regulationAI label
↓Restricts abortion accessmodel confidence 85%
Imposes federal tort liability on manufacturers of mifepristone for harms from its use in chemical abortion, increasing legal exposure for entities involved in medication abortion.
A covered entity shall be liable in accordance with this section to any individual who suffers bodily injury or harm to mental health (including any physical, psychological, emotional, or physiological harm) that is attributable, in whole or in part, to the individual's use of a covered medication manufactured by a covered entity.
✓ Quote verified word for word in the bill text
Introduced (completed)
Committee
Passed one chamber
Passed both
President
Law
Stage: Committee · step 2 of 6
Last action
2026-03-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why the model tagged it this way: The bill substantively addresses abortion by withdrawing FDA approval for mifepristone (the primary medication used for chemical abortion) and creating manufacturer liability for harms from its use, both of which restrict access to and availability of medication abortion. No other listed topics are substantively addressed.
Related bills
HR9421Ban Abortion by Mail Act↓Restricts abortion access↓Restricts abortion access Committee
HR9420Reproductive Health Care Training Act of 2026↑Expands abortion access↑Expands abortion access Committee
S4879Let Doctors Provide Reproductive Health Care Act↑Expands abortion access↑Expands abortion access Committee
S4880Dismemberment Abortion Ban Act of 2026↓Restricts abortion access↓Restricts abortion access Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2026-03-12
House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.